2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1593

Baricitinib for Rheumatoid Arthritis: A Systematic Review and Meta-Analysis
Abstract Number: 2959

Baseline Endothelial Dysfunction Might Predict Immunosuppressive Need in Young, Male Behcet’s Patients with Early Disease: A Prospective Follow-up
Abstract Number: 1702

Baseline Patient Characteristics Associated with Response to Biologic Therapy in Patients with Psoriatic Arthritis Enrolled in the Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry
Abstract Number: 28

Baseline Serum Inflammatory Biomarkers at Cohort Entry in 1974 Predicted Cardiovascular Disease (CVD) Mortality from 1995 through 2015 in a Prospective, Community-Based Study of Incident Rheumatoid Arthritis (RA) Patients and Matched Non-RA (CN) Subjects
Abstract Number: 1652

Basement Membrane Remodeling Is Significantly Increased with Rheumatoid Arthritis and Suppressed By IL6 Inhibition: Analysis of Two Phase III Clinical Trial
Abstract Number: 811

Basophils Are Activated and Stimulate Both B Cells and Fibroblasts in Systemic Sclerosis
Abstract Number: 2940

Bechet’s Disease and Sleep Quality in Korean Patients
Abstract Number: 508

Before Clinically Detectable Arthritis Develops, ACPA-Positive and ACPA-Negative Arthralgia Patients Have Different Symptoms
Abstract Number: 2963

BehçEt’s Disease in Children: Eastern Mediterranean Experience
Abstract Number: 780

Belimumab Use in African-American Patients in an U.S. Academic Medical Center
Abstract Number: 1681

Beneficial Effect of n-3 Polyunsaturated Fatty Acids on Inflammation and Analgesic Use in Psoriatic Arthritis – a Randomised, Double Blind, Placebo-Controlled Trial
Abstract Number: 12

Benefit of Early Therapy with Methotrexate and Prednisone in Patients with Early Rheumatoid Arthritis and Undifferentiated Early Arthritis (CONAART)
Abstract Number: 2779

Better Health-Related Quality of Life and Work Capacity in Patients Achieving Inactive Disease and Clinical Response in Patients with Non-Radiographic Axial Spondyloarthritis
Abstract Number: 1005

Biallelic Hypomorphic Mutations in a Linear Deubiquitinase Define Otulipenia, an Early-Onset Systemic Autoinflammatory Disease
Abstract Number: 2013

BIIB059, a Monoclonal Antibody Targeting BDCA2, Shows Evidence of Biological Activity and Early Clinical Proof of Concept in Subjects with Active Cutaneous SLE

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].